PROK Stock Analysis: Buy, Sell, or Hold?
PROK - ProKidney Corp. Class A Ordinary Shares
$2.03
0.14 (7.41%)
▲
5d:
+19.41%
30d:
+6.84%
90d:
+16.0%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When PROK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: PROK is 7.4% above its trading range ($1.89). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: PROK is 7.4% above its trading range ($1.89). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: PROK is currently trading at $2.03, which is considered extended relative to its 30-day fair value range of $1.69 to $1.89.
Technical Outlook: Technically, PROK is in a downtrend. Immediate support is located at $1.64, while resistance sits at $2.24. The stock is showing strong short-term momentum, up 7.4% recently.
Market Sentiment: PROK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.25 (+207.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PROK is in a downtrend. Immediate support is located at $1.64, while resistance sits at $2.24. The stock is showing strong short-term momentum, up 7.4% recently.
Market Sentiment: PROK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.25 (+207.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.69 -
$1.89
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+7.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.4%)
- BULLISH: Trading 207.9% below Wall St target ($6.25)
- CAUTION: Extended 7.4% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$1.69 -
$1.89
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.64
Resistance Level
$2.24
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.52
Wall Street Target
$6.25
(+207.9%)
Revenue Growth (YoY)
-1.7%
Share & Embed Analysis
Last updated: July 03, 2026 8:33 PM ET
Data refreshes hourly during market hours. Next update: 9:33 PM
Data refreshes hourly during market hours. Next update: 9:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PROK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$89 | 64 BUY |
